The consensus estimate is $1.13 per share, up 1% from a year ago when Baxter reported earnings of $1.12 per share.
The consensus estimate remains unchanged over the past month, but it has decreased from three months ago when it was $1.14. Analysts are expecting earnings of $4.65 per share for the fiscal year. Revenue is expected to be $3.70 billion for the quarter, 4% higher than the year-earlier total of $3.57 billion. For the year, revenue is projected to roll in at $15.51 billion.
The decrease in profit in the first quarter came after net income rose in the previous quarter. Net income dropped in the most recent quarter by 16% to $552 million. The quarter prior to that, net income rose 7%.
Revenue dropped in the first quarter after increasing the quarter prior. Revenue dropped 3% to $3.45 billion in the first quarter from the year earlier. In the fourth quarter, revenue rose 4%.
The majority of analysts (72%) rate Baxter as a buy. This compares favorably to the analyst ratings of its nearest 10 competitors, which average 47% buys.
Baxter International develops, manufactures and markets products related to hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. One of Baxter's main competitors in the medical equipment and supplies industry,
Other competitors in the healthcare sector include:
Earnings estimates provided by Zacks.
Narrative Science, through its proprietary artificial intelligence platform, transforms data into stories and insights.
